Indian Immunologicals Limited and ICMR Collaborate on Zika Vaccine Development

Thursday, 12 September 2024, 01:08

Indian Immunologicals Limited is partnering with ICMR for the clinical development of India's first codon de-optimized live attenuated Zika vaccine. This collaboration marks a pivotal step in combating Zika disease, primarily transmitted by mosquitoes. With rising Zika cases in India, this vaccine aims to provide essential prevention and safety during pregnancy.
Financialexpress
Indian Immunologicals Limited and ICMR Collaborate on Zika Vaccine Development

Indian Immunologicals Limited and ICMR Collaboration

Indian Immunologicals Limited (IIL) on Thursday announced that it has signed a MoA with Indian Council of Medical Research (ICMR) for clinical development of India’s first codon de-optimized live attenuated Zika vaccine. Zika disease, a viral infection, is mostly a mosquito-borne disease transmitted by Aedes mosquitoes. It can also be transmitted to the foetus during pregnancy, through sexual contact, blood transfusion, and organ transplantation.

Impact of Zika Virus

The disease is usually mild and requires no specific treatment. However, it is more serious when infection occurs during pregnancy, which may cause microcephaly and other congenital malformations in the infant, preterm birth, and miscarriage. Few cases may also develop Guillain-Barré syndrome, a neurological disorder. In India, Zika cases have been reported in several states. According to the Health Ministry, as of 22 July 2024, 537 Zika cases have been registered.

Collaboration Details

IIL has partnered with Griffith University, Australia, to develop the codon de-optimized live attenuated Zika vaccine that has completed extensive pre-clinical evaluations and received permission from the Indian regulatory authority to produce GMP grade materials for clinical development work. “It is a great moment for IIL to collaborate with ICMR to develop a Zika vaccine. IIL has been the single largest contributor to India achieving self-sufficiency in the field of vaccines,” said Dr K Anand Kumar, Managing Director, Indian Immunologicals Limited.

Funding and Trial Phases

According to the MoA, ICMR will fund the Phase I clinical trial costs, including conducting, investigating, and monitoring of clinical trials. The trial will be conducted at ICMR network sites in India. “ICMR’s Phase I trial network facilitates first-in-human safety studies for innovative and affordable Frontier MedTech, including small molecules, biologics, and vaccines. This is a significant step towards achieving Atmanirbhar Bharat and Viksit Bharat,” said Dr. Rajiv Bahl, DG-ICMR.


Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest and most reliable health updates. Stay informed and enhance your wellness knowledge effortlessly.

Subscribe